Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

AMRXNYSE / NASDAQHealthcareMid cap

$21.12-$0.27 (-1.3%)

Last close · Data as of Nov 20, 2026

Market cap
$4.3B
P/E
59.9x
EV / EBITDA
11.1x
Revenue
$3.0B
Net margin
2.4%
ROCE
14.2%

+83.4% over the last year

Amneal Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+6.5%
3M
+18.0%
6M
+72.7%
1Y
+83.4%
5Y
+357.1%

52-week range

Day change -$0.27 (-1.3%) from $21 to $21 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AMRX, bought on each weekday since 2021.

News & filings

What Amneal Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • The price is 29.8% above its 200-day average, and the 50-day average is above the 200-day.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Read moreShow less

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Sector
Healthcare
Shares outstanding
313.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.3B
P/E
59.9x
P/B
-60.9x
EV / EBITDA
11.1x
EV / Sales
2.2x
P/S
1.4x
52-week high
$21.88
52-week low
$11.52

Profitability

Operating margin
13.2%
Net margin
2.4%
EBITDA margin
20.0%
ROE
-101.8%
ROCE
14.2%
ROA
2.0%
Asset turnover
0.82

Growth

Revenue
$3.0B
Revenue growth, 1Y
8.0%
Revenue CAGR, 3Y
10.9%
Net profit growth, 1Y
-161.6%
Free cash flow
$225.6M

Solvency

Current ratio
2.17
Debt / Equity
-37.98
Debt / Assets
0.73
CFO / Net profit
4.72
Cash / Market cap
6.5%

Where the revenue went

Of every $100 of FY2025 revenue, $2 was left as net income.

Amneal Pharmaceuticals, Inc. income statement flow, FY2025
Amneal Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.9B
RevenueGross profit$1.1B
Gross profitOperating expenses$715.4M
Gross profitOperating income$397.9M
Operating incomePretax income$139.2M
Operating incomeInterest and other expense$258.7M
Pretax incomeTax and other$67.2M
Pretax incomeNet income$72.1M

Revenue and net profit

Revenue grew 8.0% in FY2025; net profit is the dashed line.

Amneal Pharmaceuticals, Inc. revenue and net profit by fiscal year
Amneal Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.2B-$130.0M
FY2023$2.4B-$84.0M
FY2024$2.8B-$116.9M
FY2025$3.0B$72.1M

Cash flows

FY2025: $340.0M from operations, $225.6M free after investment (dashed).

Amneal Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Amneal Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$65.1M-$25.5M
FY2023$345.6M$276.4M
FY2024$295.1M$220.1M
FY2025$340.0M$225.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$3.0B+8.0%1Y
EBITDA
$603.9M+37.3%1Y
Net profit
$72.1M
Cash from operations
$340.0M+15.2%1Y
Free cash flow
$225.6M+2.5%1Y
Revenue CAGR, 3Y
10.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$3.0B$603.9M$72.1M$225.6M-101.8%+8.0%-161.6%

Monthly returns

Month-by-month returns of AMRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.7B
Liabilities$3.7B
Equity-$71.3M
Paid-in capital$571.8M
Retained earnings-$535.0M
Minority interest-$540.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AMRX highlighted.

P/E against peers

AMRX trades at 59.9x earnings against a peer median of 25.2x (a 138% premium).

Not shown (no positive earnings and no EV / Sales): RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Amneal Pharmaceuticals, Inc.AMRXthis companyP/E ↑ premium$4.3B59.9x-60.9x-101.8%11.1x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
RadNet, Inc.RDNT$4.2B-222.6x3.8x-1.7%16.7x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Peer median—25.2x3.0x6.6%15.9x

Year-to-date ROI

AMRX since 1 January, against earlier years.

Historical volatility

AMRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Amneal Pharmaceuticals, Inc. operating margin by fiscal year
Amneal Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY20228.5%
FY202310.0%
FY202412.5%
FY202513.2%
LineFY2025
Cost of revenueCost Of Revenue$1.9B
Gross profitGross Profit$1.1B
Operating expensesOperating Expense$715.4M
Research and developmentResearch And Development$193.8M
Selling, general and administrativeSelling General And Administration$526.8M
Other operating expensesOther Operating Expenses-$5.2M
Total expensesTotal Expenses$2.6B
Pretax incomePretax Income$139.2M

Learn while you research

Academy chapters picked for Amneal Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 59.9, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →